Şunu aradınız:: solvent based developer solutions (İngilizce - Hırvatça)

solvent-based paclitaxel (175 mg/m2)
0,72 (0,617; 0,835)

this is possibly due to paclitaxel not being trapped in cremophor el micelles as with solvent-based paclitaxel.
moguće je da je to zbog toga što paklitaksel nije uhvaćen u micele cremophor el, kao što je slučaj s paklitakselom baziranom na otapalu.

this resulted in significantly higher exposure to unbound paclitaxel with abraxane compared with solvent-based paclitaxel, even though the total exposure is comparable.
to je rezultiralo značajno većom izloženošću nevezanom paklitakselu s lijekom abraxane u usporedbi s paklitakselom baziranom na otapalu, iako je ukupna izloženost usporediva.

the fraction of free paclitaxel was significantly higher with abraxane (6.2%) than with solvent-based paclitaxel (2.3%).
frakcija slobodnog paklitaksela bila je znatno veća s lijekom abraxane (6,2%) nego s paklitakselom baziranom na otapalu (2,3%).

the study compared abraxane in combination with carboplatin versus solvent-based paclitaxel in combination with carboplatin as first-line treatment in patients with advanced non-small cell lung cancer.
u ispitivanju se uspoređivao abraxane u kombinaciji s karboplatinom i paklitaksel na bazi otapala u kombinaciji s karboplatinom kao prva linija liječenja bolesnika s uznapredovalim karcinomom nemalih stanica pluća.

based on non-compartmental pk analysis, the plasma clearance of paclitaxel with abraxane was larger (43%) than that following a solvent-based paclitaxel injection and its volume of distribution was also higher (53%).
na temelju farmakokinetičke analize bez uključivanja odjeljaka, plazmatski klirens paklitaksela s lijekom abraxane bio je veći (43%) nego nakon primjene injekcija paklitaksela baziranog na otapalu, a i njegov volumen distribucije bio je također veći (53%).